{
    "nctId": "NCT00760370",
    "briefTitle": "Comparison of Zometa Retention and Effect in Multiple Myeloma and Breast Cancer",
    "officialTitle": "Bone Retention of Bisphosphonate (Zometa) in Patients With Multiple Myeloma or Breast Cancer With Metastases to Bone",
    "overallStatus": "COMPLETED",
    "conditions": "Multiple Myeloma, Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 60,
    "primaryOutcomeMeasure": "Amount of Zometa retained in body",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients diagnosed with breast cancer and metastases to bone.\n* Patients diagnosed with multiple myeloma.\n* Patients who are scheduled to receive Zometa.\n* Post-menopausal women (at least 10 months since last period).\n* Newly diagnosed patients must have clear signs of osteolysis.\n\nExclusion Criteria:\n\n* Anti-estrogen treatment.\n* Patients given chemotherapy during or less than 7 days before study begin.\n* Patients receiving glucocorticoids less than 5 days prior to study begin or during the study period (14 days)",
    "sex": "FEMALE",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}